Cardiovascular Systems (CSII) 10-K 23 Aug 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2019	Aug. 16, 2019	Dec. 31, 2018
Document and Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2019
Entity File Number	000-52082
Entity Registrant Name	CARDIOVASCULAR SYSTEMS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1698056
Entity Address, Address Line One	1225 Old Highway 8 Northwest
Entity Address, City or Town	St. Paul,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55112-6416
City Area Code	651
Local Phone Number	259-1600
Title of 12(b) Security	Common Stock, One-tenth of One Cent ($0.001)Par Value Per Share
Trading Symbol	CSII
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Public Float			$ 964.5
Entity Common Stock, Shares Outstanding		35,268,093
Entity Central Index Key	0001180145
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--06-30
Entity Emerging Growth Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Current assets
Cash and cash equivalents	$ 74,237	$ 116,260
Marketable securities	48,435	544
Accounts receivable, net	36,015	31,225
Inventories	18,058	16,605
Prepaid expenses and other current assets	3,330	2,977
Total current assets	180,075	167,611
Property and equipment, net	27,324	27,744
Patents, net	5,105	5,231
Other assets	6,073	2,766
Total assets	218,577	203,352
Current liabilities
Accounts payable	11,194	10,441
Accrued expenses	29,387	25,776
Deferred Revenue, Current	1,764	1,243
Total current liabilities	42,345	37,460
Long-term liabilities
Financing obligation	20,972	21,064
Deferred revenue	6,541	8,946
Other liabilities	775	1,412
Total liabilities	70,633	68,882
Commitments and contingencies
Common stock, $0.001 par value; authorized 100,000,000 common shares; issued and outstanding 34,934,569 at June 30, 2019 and 33,360,032 at June 30, 2018	34	33
Additional paid in capital	477,368	461,927
Accumulated other comprehensive income	78	101
Accumulated deficit	(329,536)	(327,591)
Total stockholders’ equity	147,944	134,470
Total liabilities and stockholders’ equity	$ 218,577	$ 203,352

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	34,934,569	33,360,032
Common stock, shares outstanding	34,934,569	33,360,032

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Document Period End Date	Jun. 30, 2019
Net revenues	$ 248,017	$ 217,043	$ 204,906
Cost of goods sold	47,680	39,484	39,441
Gross profit	200,337	177,559	165,465
Expenses:
Selling, general and administrative	167,700	148,569	144,096
Research and development	33,462	26,756	22,911
Total expenses	201,162	175,325	167,007
(Loss) income from operations	(825)	2,234	(1,542)
Interest expense	1,684	1,717	500
Interest income and other, net	(2,444)	(1,327)	(336)
Total other (income) expense, net	(760)	390	164
(Loss) income before income taxes	(65)	1,844	(1,706)
Provision for income taxes	190	132	86
Net (loss) income	$ (255)	$ 1,712	$ (1,792)
Net loss per common share:
Earnings per common share — basic	$ (0.01)	$ 0.05	$ (0.06)
Earnings per common share — diluted	$ (0.01)	$ 0.05	$ (0.06)
Weighted Average Number of Shares Outstanding, Basic	33,535,759	33,145,140	32,373,709
Weighted average common shares outstanding - diluted (in shares)	33,535,759	33,614,260	32,373,709

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss Statement - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (255)	$ 1,712	$ (1,792)
Other comprehensive income:
Unrealized gain on available-for-sale securities	78	35	66
Adjustment for net gain realized and included in interest income and other, net	0	(34)	(6)
Total change in unrealized gain on available for sale securities	78	1	60
Comprehensive (loss) income	$ (177)	$ 1,713	$ (1,732)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
Balance at beginning of period at Jun. 30, 2016	$ 100,897	$ 33	$ 428,235	$ 40	$ (327,411)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation related to restricted stock awards, net	9,412		9,412
Exercise of stock options and warrants	5,262		5,362		(100)
Employee stock purchase plan activity	4,550		4,550
Unrealized gain on available-for-sale debt securities	66			66
Net gain reclassified from accumulated other comprehensive income	(6)			(6)
Net (loss) income	(1,792)				(1,792)
Balance at end of period at Jun. 30, 2017	118,389	33	447,559	100	(329,303)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation related to restricted stock awards, net	9,546		9,546
Exercise of stock options and warrants	514		514
Employee stock purchase plan activity	4,308		4,308
Unrealized gain on available-for-sale debt securities	35			35
Net gain reclassified from accumulated other comprehensive income	(34)			(34)
Net (loss) income	1,712				1,712
Balance at end of period at Jun. 30, 2018	134,470	33	461,927	101	(327,591)
Impact from adoption of ASU 2016-01 (See Note 5)	101			(101)	101
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation related to restricted stock awards, net	10,356	1	10,355
Shares withheld for payroll taxes	(1,791)				(1,791)
Exercise of stock options and warrants	196		196
Employee stock purchase plan activity	4,890		4,890
Unrealized gain on available-for-sale debt securities	78			78
Net gain reclassified from accumulated other comprehensive income	0
Net (loss) income	(255)				(255)
Balance at end of period at Jun. 30, 2019	$ 147,944	$ 34	$ 477,368	$ 78	$ (329,536)

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Lower range of exercise of stock options and warrants (in usd per share)	$ 7.90	$ 7.90	$ 5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	12.37
Common Stock
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	5.01
Upper range of exercise of stock options and warrants (in usd per share)	12.19	12.37	12.37
Additional Paid In Capital
Lower range of exercise of stock options and warrants (in usd per share)	7.90	7.90	5.01
Upper range of exercise of stock options and warrants (in usd per share)	$ 12.19	$ 12.37	$ 12.37

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities
Net (loss) income	$ (255)	$ 1,712	$ (1,792)
Adjustments to reconcile net (loss) income to net cash provided by operating activities
Depreciation of property and equipment	3,150	3,730	3,917
Provision for (recovery of) doubtful accounts (including note receivable)	125	125	465
Provision for (recovery of) doubtful accounts (including note receivable)		(225)
Amortization of patents	296	204	218
Write-off of patent costs	800	497	733
Stock-based compensation	11,266	10,302	10,354
Accretion of discount on marketable securities	(55)	0	0
Loss on disposal of property and equipment and other	42	16	296
Changes in assets and liabilities
Accounts receivable	(4,915)	(2,878)	(5,809)
Inventories	(1,453)	292	543
Prepaid expenses and other assets	(393)	2,308	(1,823)
Accounts payable	566	104	1,761
Accrued expenses and other liabilities	2,918	(6,577)	725
Deferred revenue	(1,884)	189	10,000
Net cash provided by operating activities	10,208	9,674	19,588
Cash flows from investing activities
Expenditures for property and equipment	(2,665)	(1,956)	(981)
Purchases of long-term investments	(3,055)	(2,538)	0
Purchases of marketable securities	(47,892)	0	0
Sales of marketable securities	150	194	46
Costs incurred in connection with patents	(890)	(1,113)	(844)
Proceeds from convertible note receivable	0	318	0
Net cash used in investing activities	(54,352)	(5,095)	(1,779)
Cash flows from financing activities
Proceeds from the employee stock purchase plan	3,752	3,242	3,254
Payment of employee taxes related to vested restricted stock	(1,791)	0	0
Exercise of stock options	196	513	5,263
Proceeds from financing	0	0	20,944
Other	(36)	14	4
Net cash provided by financing activities	2,121	3,769	29,465
Net change in cash and cash equivalents	(42,023)	8,348	47,274
Cash and cash equivalents
Beginning of period	116,260	107,912	60,638
End of period	74,237	116,260	107,912
Supplemental cash flow information
Interest paid	$ 1,684	$ 1,717	$ 500

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Company Description Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minn., is a medical technology company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive income, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts. Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents. Marketable Securities The Company’s marketable securities consist predominately of available-for-sale debt securities and were valued in accordance with the fair value measurement guidance. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income, net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale equity securities are carried at fair value with any unrealized gains or losses reported in earnings. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income. Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days . Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balance at June 30, 2016 $ 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 800 Provision for doubtful accounts 125 Write-offs (312 ) Balance at June 30, 2019 $ 613 Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. The Company writes down its inventories as it becomes aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions. Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five years to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations. Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years . The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment. Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value. Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets. Financing Obligation In March 2017, the Company entered into an agreement to lease its Minnesota facility. The lease agreement has an initial term of fifteen years , with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of its Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944 . As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet. Revenue Recognition Effective July 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers using the modified retrospective adoption method. Adoption did not have a material impact on the Company’s financial statements. The Company sells its peripheral and coronary products to customers through a direct sales force in the United States and through distributors internationally and has no material concentration of credit risk or significant payment terms extended to customers and, therefore, the Company does not adjust the promised amount of consideration for the effects of a significant financing component. Sales, use, value-added, and other excise taxes are not recognized in revenue. The Company has elected to present revenue net of sales taxes and other similar taxes. Performance Obligations The majority of the Company’s revenues are from customer arrangements containing a single performance obligation to transfer peripheral and coronary products, and thus revenue is recognized at a point in time when control is transferred. This generally occurs upon shipment or upon delivery to the customer site, based on the contract terms. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company did not recognize any material revenue in the current reporting period for performance obligations that were fully satisfied in previous periods. Significant Judgments The Company has an exclusive distribution agreement with Medikit to sell the Company’s coronary and peripheral OAS in Japan. To secure exclusive distribution rights, Medikit made an upfront payment of $10,000 to the Company, which is partially refundable based on the occurrence of certain events during the term of the agreement. The Company has classified the payment as current or long-term based on its expectation of when revenue will be recognized and this expectation is re-evaluated on a quarterly basis. Medikit also provides advance payments for orders under the terms of the agreement, and, therefore, deferred revenue is recorded until products are accepted by Medikit. Revenue is recognized at the transaction price to which the Company expects to be entitled. The Company offers customers certain volume-based rebates, discounts, and incentives. Estimates of variable consideration from these items are taken into account using the most-likely amount method based on contractual provisions, the Company’s historical experience, and forecasted customer buying patterns. These items are recognized as a reduction to revenue in the period the revenue is recognized and recorded as a liability. Return and warranty obligations vary by the specific terms of agreements with customers. The Company generally does not provide customers with a right of return. The Company has a limited warranty provision for goods that are nonconforming or defective at the time of shipment, which is estimated based on historical experience. Contract Costs Commissions are earned by the Company’s direct sales force based on sales of the Company’s OAS and other products. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period of the asset that the Company would have otherwise recognized is one year or less. Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balance at June 30, 2016 $ 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 132 Provision 502 Claims (501 ) Balance at June 30, 2019 $ 133 Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred. Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the United States of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applied to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017, and in January 2018, another temporary two year suspension of the tax was passed, extending the suspension to December 31, 2019. Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization and fees, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base. Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2019 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information. Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material. Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest. Subsequent Event On August 5, 2019, the Company acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd. Upon closing, the Company made an initial $5,600 cash outlay and issued Gardia 31,493 shares of Common Stock of the Company valued at $1,400 . Following the successful completion of the manufacturing transfer of the WIRION system to the Company, the Company has agreed to pay Gardia an additional $10,000 , half of which may be paid by the Company through an additional issuance of shares of Common Stock. In addition, the Company has agreed to make a performance milestone payment to Gardia equal to $3,000 for each $10,000 in net revenues recognized by the Company from sales of the WIRION system for applications above-the-knee in excess of $30,000 during the 36 month period beginning on the earlier of the first commercial sale of the system by the Company or six months following successful manufacturing transfer. The initial accounting for this acquisition will be completed in the first quarter of fiscal 2020. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. The guidance is effective for the Company on July 1, 2019. The Company will elect the prospective transition method with the effects of adoption recognized as a cumulative effect adjustment to the opening balance of retained earnings in the Company's fiscal 2020 financial statements, with no restatement of comparative periods. The Company will also elect the package of three practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. The Company has assessed the impact of adopting this guidance on its consolidated financial statements and related disclosures and does not expect a material impact to its results of operations and cash flows. The Company will record its operating leases on its consolidated balance sheet as right of use assets and lease liabilities, but due to the makeup of its current operating lease portfolio, does not expect a material amount to be recognized on the consolidated balance sheet. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption.

Selected Consolidated Financial

Selected Consolidated Financial Statement Information	12 Months Ended
	Jun. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected Consolidated Financial Statement Information	2. Selected Consolidated Financial Statement Information Accounts Receivable, Net Accounts receivable consists of the following: June 30, 2019 2018 Accounts receivable $ 36,628 $ 32,025 Less: Allowance for doubtful accounts (613 ) (800 ) Accounts receivable, net $ 36,015 $ 31,225 Inventories Inventories consist of the following: June 30, 2019 2018 Raw materials $ 5,547 $ 6,820 Work in process 1,415 1,315 Finished goods 11,096 8,470 Inventories $ 18,058 $ 16,605 Property and Equipment, Net Property and equipment consists of the following: June 30, 2019 2018 Land $ 572 $ 500 Building 22,420 22,420 Equipment 17,517 16,510 Furniture 2,975 2,709 Leasehold improvements 540 438 Construction in progress 1,328 1,110 45,352 43,687 Less: Accumulated depreciation (18,028 ) (15,943 ) Total Property and equipment, net $ 27,324 $ 27,744 On December 29, 2016, the Company entered into a Purchase and Sale Agreement, as subsequently amended (collectively, the “Sale Agreement”), with Krishna Holdings, LLC (the “Buyer”), providing for the sale to Buyer of the Company’s headquarters facility in St. Paul, Minnesota (the “Facility”), for a cash purchase price of $21,500 . On March 30, 2017, the sale of the Facility under the Sale Agreement closed. The Company received proceeds of approximately $20,944 ( $21,500 , less $556 of transaction expenses). The net proceeds are to be used for working capital and general corporate purposes. In connection with the sale, the Company recorded an impairment charge of $158 . Under the Sale Agreement, the Company entered into a Lease Agreement (the “Lease Agreement”) with Krishna Holdings, LLC, Apex Holdings, LLC, Kashi Associates, LLC, Keva Holdings, LLC, S&V Ventures, LLC, Polo Group LLC, SPAV Holdings LLC, Star Associates LLC, and The Global Villa, LLC. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of the Facility as a financing transaction where the assets remain on the Company’s balance sheet. See Note 4 for further discussion on future payment obligations under the Lease Agreement. Patents, net Patents, net consist of the following: June 30, 2019 2018 Patents $ 6,093 $ 6,435 Less: Accumulated amortization (988 ) (1,204 ) Total Patents, net $ 5,105 $ 5,231 As of June 30, 2019, future estimated amortization of patents is as follows: 2020 $ 209 2021 209 2022 207 2023 201 2024 197 Thereafter 4,082 $ 5,105 This future amortization expense is an estimate. Actual amounts may vary from these estimated amounts due to additional intangible asset acquisitions, approval of patents-in-process, potential impairment, change in useful life or other events. Accrued Expenses Accrued expenses consist of the following: June 30, 2019 2018 Salaries and bonus $ 11,105 $ 6,624 Commissions 6,829 7,234 Accrued vacation 4,230 3,557 Accrued excise, sales and other taxes 3,349 3,522 Clinical studies 2,092 1,422 Legal settlement 467 1,847 Other accrued expenses 1,315 1,570 Total Accrued expenses $ 29,387 $ 25,776 Legal Settlement On June 28, 2016, the Company entered into a Settlement Agreement (the “Settlement Agreement”) with the United States of America, acting through the Department of Justice (the “DOJ”) and on behalf of the Office of Inspector General of the Department of Health and Human Services, and Travis Thams, to resolve the investigation by the DOJ and the civil action underlying such investigation. Under the Settlement Agreement, the Company agreed to pay $8,000 (the “Settlement Amount”), as follows: an initial payment of $3,000 , paid on July 1, 2016, with the remaining $5,000 , which bears interest at 1.8% per annum, payable in 11 equal quarterly installments, beginning January 1, 2017. The final quarterly installment made on July 1, 2019 is included in accrued expenses (as noted in the table above). Under the Settlement Agreement, if the Company makes a single payment in excess of $2,000 , which payment is not covered by an insurance policy, in settlement of any claims before paying the full Settlement Amount, the remaining unpaid balance of the Settlement Amount will become immediately due and payable, with interest accruing on the unpaid principal portion at an interest rate of 1.8% per annum.

Revenue Revenue

Revenue Revenue	12 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue A summary of the Company’s accounting policies related to revenue recognition in accordance with ASC 606 can be found within Note 1 of these financial statements. The following table disaggregates the Company’s net revenues by product category and geography for the following periods: Year Ended June 30, Product Category 2019 2018 2017 Peripheral $ 178,896 $ 161,405 $ 153,716 Coronary 69,121 55,638 51,190 Total net revenues $ 248,017 $ 217,043 $ 204,906 Geography United States $ 240,114 $ 215,233 $ 204,906 International 7,903 1,810 — Total net revenues $ 248,017 $ 217,043 $ 204,906 Revenue of $1,312 was recognized in the year ended June 30, 2019 that was deferred as of June 30, 2018 . As of June 30, 2019 and June 30, 2018 , the Company had a liability of $1,958 and $1,398

Debt

Debt	12 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	. Debt Revolving Credit Facility On March 31, 2017, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Silicon Valley Bank (“SVB”). The Loan Agreement provides for a senior, secured revolving credit facility (the “Revolver”) of $40,000 (the “Maximum Dollar Amount”). Advances under the Revolver may be made from time to time up to the Maximum Dollar Amount, subject to certain borrowing limitations. The Revolver has a maturity date of March 31, 2020 and bears interest at a floating per annum rate equal to the Wall Street Journal prime rate, less 0.25% . Interest on borrowings is due monthly and the principal balance is due at maturity. Borrowings up to $10,000 are available on a non-formula basis. Borrowings above $10,000 are based on (i) 85% of eligible domestic accounts receivable, and (ii) the lesser of 50% of eligible inventory or $5,000 , subject to adjustment as defined in the Loan Agreement. Upon the Revolver’s maturity, any outstanding principal balance, unpaid accrued interest, and all other obligations under the Revolver will be due and payable. The Company will incur a fee equal to 1% of the Maximum Dollar Amount upon termination of the Loan Agreement or the Revolver for any reason prior to the maturity date, unless refinanced with SVB. The Company’s obligations under the Loan Agreement are secured by certain of the Company’s assets, including, among other things, accounts receivable, deposit accounts, inventory, equipment, general intangibles and records pertaining to the foregoing. The collateral does not include the Company’s intellectual property, but the Company has agreed not to encumber its intellectual property without the consent of SVB. The Loan Agreement contains customary covenants limiting the Company’s ability to, among other things, incur debt or liens, make certain investments and loans, enter into transactions with affiliates, undergo certain fundamental changes, dispose of assets, or change the nature of its business. In addition, the Loan Agreement contains financial covenants requiring the Company to maintain, at all times when any amounts are outstanding under the Revolver, either (i) minimum unrestricted cash at SVB and unused availability on the Revolver of at least $10,000 or (ii) minimum trailing three-month Adjusted EBITDA of $1,000 . If the Company does not comply with the various covenants under the Loan Agreement, the interest rate on outstanding amounts will increase by 5% and SVB may, subject to various customary cure rights, decline to provide additional advances under the Revolver, require the immediate payment of all amounts outstanding under the Revolver, and foreclose on all collateral. Under the Loan Agreement, the Company paid SVB a non-refundable commitment fee of $80 , which is being amortized to interest expense over the term of the Loan Agreement. The Company is required to pay a fee equal to 0.35% per annum on the unused portion of the Revolver, payable quarterly in arrears. SVB’s obligations to advance funds under the Revolver are subject to an initial collateral examination to be completed within 90 days of the effective date of the Loan Agreement. The Company is not obligated to draw any funds under the Revolver and no amounts were outstanding as of June 30, 2019 and 2018. Financing Obligation In connection with the sale of the Facility, the Company entered into a Lease Agreement to lease the Facility. The Lease Agreement has an initial term of 15 years , with four consecutive renewal options of 5 years each at the Company’s option, with a base annual rent in the first year of $1,638 and annual escalations of 3% thereafter. Rent during subsequent renewal terms will be at the then fair market rental rate. The effective interest rate is 7.89% . Future payments under the initial term of the Lease Agreement as of June 30, 2019 are as follows: 2020 $ 1,750 2021 1,803 2022 1,857 2023 1,913 2024 1,970 Thereafter 17,405 $ 26,698

Marketable Securities & Fair Va

Marketable Securities & Fair Value Measurements	12 Months Ended
	Jun. 30, 2019
Compensation Related Costs [Abstract]
Fair Value Disclosures [Text Block]	5. Marketable Securities & Fair Value Measurements The Company’s marketable securities at June 30, 2019 and 2018 are classified on the consolidated balance sheet as follows: June 30, 2019 2018 Short-term available-for-sale debt securities $ 38,193 $ — Long-term available-for-sale debt securities 9,832 — Available-for-sale debt securities 48,025 — Mutual funds 410 544 Total marketable securities $ 48,435 $ 544 Effective July 1, 2018 the Company adopted the provisions of ASU 2016-01. Upon adoption, the Company recorded a cumulative-effect reclassification adjustment of $101 from accumulated other comprehensive income to the opening balance of retained earnings as of July 1, 2018. Unrealized gains and losses of marketable securities in equity investments, denoted as mutual funds, previously recognized in other comprehensive income, will now be recognized in net income as a component of other income. Available-for-sale debt securities at June 30, 2019 are invested in the following financial instruments: As of June 30, 2019 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 14,277 $ — $ — $ 14,277 Corporate debt 26,466 64 — 26,530 Asset backed securities 7,204 14 — 7,218 Total available-for-sale debt securities $ 47,947 $ 78 $ — $ 48,025 The Company did not hold any available-for-sale debt securities at June 30, 2018 . There were no other-than-temporary impairments during the years ended June 30, 2019 and 2018 . During the year ended June 30, 2018 there was a realized gain of $34 that was recorded within interest income and other, net on the consolidated statement of operations associated with the mutual funds, prior to the adoption of ASU 2016-01. The Company’s marketable securities are measured at fair value on a recurring basis. The following tables set forth the Company’s marketable securities measured at fair value by level within the fair value hierarchy as of June 30, 2019 and 2018 : Fair Value Measurements as of June 30, 2019 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Commercial paper $ 14,277 — 14,277 $ — Corporate debt $ 26,530 — 26,530 $ — Asset backed securities $ 7,218 — 7,218 $ — Mutual funds $ 410 121 289 $ — Total marketable securities $ 48,435 121 48,314 $ — Fair Value Measurements as of June 30, 2018 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 544 199 345 $ — Total marketable securities $ 544 199 345 $ — There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the year ended June 30, 2019 . Any transfers between levels are recognized on the date of the event or when a change in circumstances causes a transfer. Non-Marketable Equity Investment The Company holds an equity investment that does not have a readily determined fair value. The Company has elected to measure this investment at cost minus impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is reviewed each reporting period by performing a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired. As of June 30, 2019 and 2018 , the carrying value of the investment was $5,593 and $2,538 , respectively. During the year ended June 30, 2019 , no observable price changes or impairment indicators were noted. The investment is recorded within other long term assets on the consolidated balance sheet.

Stock Options and Restricted St

Stock Options and Restricted Stock Awards	12 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock Options and Restricted Stock Awards	. Stock-Based Compensation On November 15, 2017, the Company’s stockholders approved the 2017 Equity Incentive Plan (the “2017 Plan”) for the purpose of granting equity awards to employees, directors, and consultants. The 2017 Plan replaced the 2014 Equity Incentive Plan (the “2014 Plan”), and no further equity awards may be granted under the 2014 Plan or the 2007 Equity Incentive Plan (the “2007 Plan”) (the 2017 Plan, 2014 Plan and the 2007 Plan are collectively referred to as the “Plans”). The 2017 Plan allows for the granting of up to 3,607,523 shares of common stock as approved by the Board of Directors or committees thereof in the form of nonqualified or incentive stock options, restricted stock awards, restricted stock unit awards, performance share awards, performance unit awards or stock appreciation rights to officers, directors, consultants and employees of the Company. As of June 30, 2019 , there were 2,085,025 shares available for grant under the 2017 Plan. Equity awards classified as restricted stock and performance-based restricted stock are treated as issued shares when granted; however, these shares are not included in the computation of basic weighted average shares outstanding. When shares vest, unless the holder elects to pay the payroll tax liability in cash or through a sale of shares, the Company withholds the appropriate amount of shares to settle the payroll tax liability, on behalf of the individual receiving the shares, as an adjustment to accumulated deficit. Stock Options All options granted under the Plans become exercisable over periods established at the date of grant. The option exercise price is generally not less than the estimated fair market value of the Company’s common stock at the date of grant, as determined by the Company’s management and Board of Directors. In addition, the Company has granted nonqualified stock options to a director outside of the Plans. Stock option activity is as follows: Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Forfeited or expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07 Exercised (55,880 ) $ 9.20 Options outstanding at June 30, 2018 22,321 $ 8.75 Exercised (22,321 ) $ 8.75 Options outstanding at June 30, 2019 — $ — As of June 30, 2019 , no options are outstanding. The Company determined the fair value of options using the Black-Scholes option pricing model. The estimated fair value of options, including the effect of estimated forfeitures, was recognized as expense on a straight-line basis over the options’ vesting periods. There were no options granted during the years ended June 30, 2019 , 2018 or 2017 . The aggregate intrinsic value of a stock option award is the amount by which the market value of the underlying stock exceeds the exercise price of the award. The aggregate intrinsic value for vested and outstanding options at June 30, 2019 , 2018 and 2017 , was $0 , $527 and $1,811 , respectively. The total aggregate intrinsic value of options exercised during the years ended June 30, 2019 , 2018 and 2017 , was $553 , $1,095 , and $7,955 , respectively. Shares supporting option exercises are sourced from new share issuances. Restricted Stock The fair value of each restricted stock award was equal to the fair market value of the Company’s common stock at the date of grant. Vesting of time based restricted stock awards ranges from one year to three years . The estimated fair value of restricted stock awards, including the effect of estimated forfeitures, is recognized on a straight-line basis over the restricted stock’s vesting period. Restricted stock award activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26 Granted 290,856 $ 27.93 Forfeited (68,499 ) $ 22.76 Vested (253,725 ) $ 22.87 Outstanding at June 30, 2018 455,216 $ 24.77 Granted 262,727 $ 35.53 Forfeited (27,143 ) $ 29.05 Vested (215,855 ) $ 23.23 Outstanding at June 30, 2019 474,945 $ 31.36 Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2019 , 2018 and 2017 , the Company estimated its weighted average forfeiture rate at 18.0% , 15.2% and 17.1% , respectively. As of June 30, 2019 , there was approximately $11,016 of total unrecognized compensation expense, net of the effect of estimated forfeitures, related to nonvested restricted stock awards, which is expected to be recognized over a weighted-average period of 1.6 years . Performance-Based Restricted Stock The Company also grants performance-based restricted stock awards to certain executives and other management. Fiscal 2019 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2018 compared to the closing prices for the 90 trading days preceding July 1, 2021. Fiscal 2018 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2017 compared to the closing prices for the 90 trading days preceding July 1, 2020. Fiscal 2017 awards vest based on the Company’s total shareholder return relative to total shareholder return of the peer group (a market condition), as measured by the closing prices of the stock of the Company and its peer group for the 90 trading days preceding July 1, 2016 compared to the closing prices for the 90 trading days preceding July 1, 2019. The aggregate maximum shares granted were as follows: Performance Measurement 2019 2018 2017 Total shareholder return 225,325 278,889 336,826 Performance-based restricted stock award activity is as follows: Number of Weighted Average Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97 Granted 278,889 $ 13.63 Forfeited (66,295 ) $ 13.17 Outstanding at June 30, 2018 531,178 $ 12.69 Granted 225,325 $ 22.33 Forfeited (2,631 ) $ 18.64 Outstanding at June 30, 2019 753,872 $ 15.20 Estimated pre-vesting forfeitures are considered in determining stock-based compensation expense. As of June 30, 2019 , there was approximately $4,078 of total unrecognized compensation expense related to nonvested performance-based restricted stock awards, which is expected to be recognized over a weighted-average period of 1.8 years . Stock-based compensation expense associated with performance-based restricted stock was $3,497 for the year ended June 30, 2019 . Restricted Stock Units The Company grants restricted stock units to members of its Board of Directors. Restricted stock units represent the right to receive payment in the form of shares of the Company’s common stock or in cash at the Company’s option. Restricted stock unit payments occur within 30 days following the six month anniversary of the date that the director ceases to serve on the Board of Directors or, if the restricted stock units are granted in lieu of an annual cash retainer, on the payment date selected by the director that is at least two years after the grant date. The estimated fair value of restricted stock units is recognized on a straight-line basis over the vesting period. Restricted stock unit activity is as follows: Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Converted to common stock (6,476 ) $ 29.34 Forfeited (2,974 ) $ 21.01 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73 Granted 28,364 $ 31.02 Converted to common stock (41,925 ) $ 16.07 Restricted stock units outstanding at June 30, 2018 335,869 $ 15.94 Granted 21,162 $ 38.28 Converted to common stock (2,855 ) $ 21.01 Restricted stock units outstanding at June 30, 2019 354,176 $ 17.23 Employee Stock Purchase Plan The Company maintains an employee stock purchase plan that was approved by the Company’s stockholders in November 2015 (“2015 ESPP”) and replaced the previous employee stock purchase plan that expired on May 31, 2016. The 2015 ESPP provides eligible employees the opportunity to acquire common stock in accordance with Section 423 of the Internal Revenue Code of 1986. Stock can be purchased each 6 month period per year (twice per year). The purchase price is equal to 85% of the lower of the price at the beginning or the end of the respective period. Employees purchased 155,394 shares at an average price of $24.14 per share during the year ended June 30, 2019 . Shares reserved under the 2015 ESPP at June 30, 2019 totaled 1,530,037 . Stock-Based Compensation Expense The following amounts were recognized as stock-based compensation expense in the consolidated statements of operations: Year Ended June 30, 2019 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 281 $ — $ 65 $ 346 Selling, general and administrative 7,899 810 905 9,614 Research and development 1,136 — 170 1,306 Total stock-based compensation expense $ 9,316 $ 810 $ 1,140 $ 11,266 Year Ended June 30, 2018 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 207 $ — $ 68 $ 275 Selling, general and administrative 7,462 750 848 9,060 Research and development 817 — 150 967 Total stock-based compensation expense $ 8,486 $ 750 $ 1,066 $ 10,302 Year Ended June 30, 2017 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 588 $ — $ 101 $ 689 Selling, general and administrative 6,568 1,024 1,065 8,657 Research and development 879 — 129 1,008 Total stock-based compensation expense $ 8,035 $ 1,024 $ 1,295 $ 10,354

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The components of the Company’s overall deferred tax assets and liabilities are as follows: June 30, 2019 2018 Deferred tax assets Stock-based compensation $ 3,803 $ 2,505 Deferred revenue 2,032 2,351 Accrued expenses and compensation 1,058 1,103 Other 1,062 1,022 Research and development credit carryforwards 5,161 5,048 Net operating loss carryforwards 65,628 64,101 Total deferred tax assets 78,744 76,130 Valuation allowance (78,744 ) (76,130 ) Net deferred tax assets $ — $ — On December 22, 2017, the United States enacted tax reform legislation commonly known as the Tax Cuts and Jobs Act (the “Act”), resulting in significant modifications to existing law. Accounting for the income tax effects of the Act which impacted the Company’s tax provision has been completed as of the current year and included in the Company’s financial statements as of June 30, 2018. As a result of the Act, the Company remeasured deferred tax assets and liabilities from 34% to 21%, but given the Company is in a full valuation allowance position, there was no tax expense impact. The Company has established valuation allowances to fully offset its deferred tax assets due to the uncertainty about the Company’s ability to generate the future taxable income necessary to realize these deferred assets, particularly in light of the Company’s historical losses. The future use of net operating loss carryforwards is dependent on the Company attaining profitable operations, and may be limited in any one year under Internal Revenue Code Section 382 due to significant ownership changes, as defined under such Section, as a result of the Company’s equity financings. A summary of the valuation allowances are as follows: Balances at June 30, 2016 $ 101,217 Reductions (186 ) Balance at June 30, 2017 101,031 Reductions (24,901 ) Balance at June 30, 2018 76,130 Additions 2,614 Balance at June 30, 2019 $ 78,744 As of June 30, 2019 and 2018 , the Company had federal tax net operating loss carryforwards of approximately $269,433 and $275,030 , respectively. These net operating loss carryforwards are available to offset taxable income through 2037. The Company also had various state net operating loss carryforwards available to offset future state taxable income. These state net operating loss carryforwards typically have the same expirations as the Company’s federal tax net operating loss carryforwards. As of June 30, 2019 and 2018 , the Company had approximately $4,314 and $4,244 of federal research and development credit carryforwards, respectively. As of June 30, 2019 and 2018 , the Company had approximately $1,798 and $ 1,560 of state research and development credit carryforwards. The federal and state research and development credit carryforwards will expire through fiscal 2038 and 2033, respectively. As required by FASB ASC Topic 740, “Income Taxes,” the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recorded a liability relating to unrecognized tax benefits of $611 and $597 at June 30, 2019 and 2018 , respectively. Due to the Company having a full valuation allowance, this liability has been netted against the deferred tax asset. The Company recognizes interest and penalties related to uncertain tax provisions as part of the provision for income taxes. The Company has not currently reserved for any interest or penalties for such reserves due to the Company being in an net operating loss position. The Company does not expect to recognize any benefits from the unrecognized tax benefits within the next twelve months. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Balances at June 30, 2016 $ 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balances at June 30, 2017 570 Decreases related to prior year tax positions (3 ) Increases related to current year tax positions 30 Balance at June 30, 2018 597 Decreases related to prior year tax positions (11 ) Increases related to current year tax positions 25 Balance at June 30, 2019 $ 611 The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is potentially subject to income tax examinations by tax authorities for the tax years ended June 30, 2019, 2018, 2017, and 2016. The Company is not currently under examination by any taxing jurisdiction.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases The Company leases manufacturing space and equipment under lease agreements that expire at various dates through April 2024 . Rental expenses were $540 , $652 , and $656 , for the years ended June 30, 2019 , 2018 , and 2017 , respectively. Future minimum lease payments under the agreements as of June 30, 2019 are as follows: 2020 $ 392 2021 36 2022 8 2023 3 2024 2 Thereafter — $ 441 Other Matters In the ordinary conduct of business, the Company is subject to various lawsuits and claims covering a wide range of matters including, but not limited to, employment claims and commercial disputes. While the outcome of these matters is uncertain, the Company does not believe there are any significant matters as of June 30, 2019 that are probable or estimable, for which the outcome is reasonably possible of having a material adverse impact on its consolidated balance sheets or statements of operations.

Employee Benefits

Employee Benefits	12 Months Ended
	Jun. 30, 2019
Retirement Benefits [Abstract]
Employee Benefits	9. Employee Benefits The Company offers a 401(k) plan to its employees. Eligible employees may authorize up to $19 of their annual compensation as a contribution to the plan, subject to Internal Revenue Service limitations. The plan also allows eligible employees over 50 years old to contribute an additional $6 subject to Internal Revenue Service limitations. All employees must be at least 21 years of age to participate in the plan. The Company did not provide any employer matching contributions for the years ended June 30, 2019 , 2018 , and 2017 . The Company offers certain members of management and highly compensated employees the opportunity to defer up to 100% of their base salary (after 401(k), payroll tax and other deductions), performance bonus and discretionary bonus and elect to receive the deferred compensation at a fixed future date of participant’s choosing. Each participant may, at the time of his or her deferral election, choose to allocate the deferred compensation into investment alternatives set by the Human Resources and Compensation Committee. The amount payable to each participant under the plan will change in value based upon the investment selected by that participant and is classified as current or long-term on the Company’s balance sheet based on the disbursement elections made by the participants. As of June 30, 2019 , $82 of the amount is included in accrued expenses and $328 is included in other liabilities on the consolidated balance sheet.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	10. Earnings Per Share The following table presents a reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations (in thousands except share and per share amounts): Year Ended June 30, 2019 2018 2017 Numerator Net income (loss) $ (255 ) $ 1,712 $ (1,792 ) Income allocated to participating securities — (19 ) — Net income (loss) available to common stockholders $ (255 ) $ 1,693 $ (1,792 ) Denominator Weighted average common shares outstanding — basic 33,535,759 33,145,140 32,373,709 Effect of dilutive stock options (1) — 15,039 — Effect of dilutive restricted stock units (2) — 335,869 — Effect of performance-based restricted stock awards (3) — 118,212 — Weighted average common shares outstanding — diluted 33,535,759 33,614,260 32,373,709 Earnings per common share — basic $ (0.01 ) $ 0.05 $ (0.06 ) Earnings per common share — diluted $ (0.01 ) $ 0.05 $ (0.06 ) (1) At June 30, 2018 , and 2017 ; 22,321 , and 78,201 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive. No stock options were outstanding at June 30, 2019. (2) At June 30, 2019 , 2018 , and 2017 ; 354,176 , 335,869 and 349,430 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive. (3) At June 30, 2019 , 2018 , and 2017 ; 753,872 , 531,178 , and 318,584 respectively, of performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive. Unvested time-based restricted stock awards that contain nonforfeitable rights to dividends are participating securities and included in the computation of earnings per share pursuant to the two-class method. Under this method, earnings attributable to the Company are allocated between common stockholders and the participating awards, as if the awards were a second class of stock. During periods of net income, the calculation of earnings per share excludes the income attributable to participating securities in the numerator and the dilutive impact of these securities from the denominator. In the event of a net loss, undistributed earnings are not allocated to participating securities and the denominator excludes the dilutive impact of these securities as they do not share in the losses of the Company. During the year ended June 30, 2018 , undistributed earnings allocated to participating securities were based on 382,476 unvested time-based restricted stock awards.

Quarterly Data (Unaudited)

Quarterly Data (Unaudited)	12 Months Ended
	Jun. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Data (Unaudited)	11. Quarterly Data (Unaudited) The following table sets forth the Company’s unaudited quarterly summary consolidated statements of operations in each of the quarters for the years ended June 30, 2019 and 2018 . The information for each of these quarters is unaudited and has been prepared on the same basis as the consolidated financial statements. This data should be read in conjunction with the consolidated financial statements and related notes. These operating results may not be indicative of results to be expected for any future period (amounts in thousands, except per share data). 2019 Q1 Q2 Q3 Q4 Year Total Net revenue $ 56,266 $ 60,206 $ 63,311 $ 68,234 $ 248,017 Gross profit $ 45,691 $ 48,729 $ 51,145 $ 54,772 $ 200,337 Net income (loss) $ (2,888 ) $ 492 $ 672 $ 1,469 $ (255 ) Earnings per common share - basic (1) $ (0.09 ) $ 0.01 $ 0.02 $ 0.04 $ (0.01 ) Earnings per common share - diluted (1) $ (0.09 ) $ 0.01 $ 0.02 $ 0.04 $ (0.01 ) 2018 Q1 Q2 Q3 Q4 Year Total Net revenue $ 49,676 $ 52,628 $ 55,587 $ 59,152 $ 217,043 Gross profit $ 40,474 $ 43,129 $ 45,618 $ 48,338 $ 177,559 Net income (loss) $ (1,977 ) $ (413 ) $ 365 $ 3,737 $ 1,712 Earnings per common share - basic (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 Earnings per common share - diluted (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Effective July 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers using the modified retrospective adoption method. Adoption did not have a material impact on the Company’s financial statements. The Company sells its peripheral and coronary products to customers through a direct sales force in the United States and through distributors internationally and has no material concentration of credit risk or significant payment terms extended to customers and, therefore, the Company does not adjust the promised amount of consideration for the effects of a significant financing component. Sales, use, value-added, and other excise taxes are not recognized in revenue. The Company has elected to present revenue net of sales taxes and other similar taxes. Performance Obligations The majority of the Company’s revenues are from customer arrangements containing a single performance obligation to transfer peripheral and coronary products, and thus revenue is recognized at a point in time when control is transferred. This generally occurs upon shipment or upon delivery to the customer site, based on the contract terms. Shipping and handling activities are considered to be fulfillment activities and are not considered to be a separate performance obligation. The Company does not assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract with the customer. The Company does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The Company did not recognize any material revenue in the current reporting period for performance obligations that were fully satisfied in previous periods. Significant Judgments The Company has an exclusive distribution agreement with Medikit to sell the Company’s coronary and peripheral OAS in Japan. To secure exclusive distribution rights, Medikit made an upfront payment of $10,000 to the Company, which is partially refundable based on the occurrence of certain events during the term of the agreement. The Company has classified the payment as current or long-term based on its expectation of when revenue will be recognized and this expectation is re-evaluated on a quarterly basis. Medikit also provides advance payments for orders under the terms of the agreement, and, therefore, deferred revenue is recorded until products are accepted by Medikit. Revenue is recognized at the transaction price to which the Company expects to be entitled. The Company offers customers certain volume-based rebates, discounts, and incentives. Estimates of variable consideration from these items are taken into account using the most-likely amount method based on contractual provisions, the Company’s historical experience, and forecasted customer buying patterns. These items are recognized as a reduction to revenue in the period the revenue is recognized and recorded as a liability. Return and warranty obligations vary by the specific terms of agreements with customers. The Company generally does not provide customers with a right of return. The Company has a limited warranty provision for goods that are nonconforming or defective at the time of shipment, which is estimated based on historical experience. Contract Costs Commissions are earned by the Company’s direct sales force based on sales of the Company’s OAS and other products. The Company applies the practical expedient and recognizes commissions as an expense when incurred because the amortization period of the asset that the Company would have otherwise recognized is one year or less.
Company Description	Company Description Cardiovascular Systems, Inc. (the “Company”), based in St. Paul, Minn., is a medical technology company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The Company’s Orbital Atherectomy Systems (“OAS”) treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.
Principles of Consolidation	Principles of Consolidation The consolidated balance sheets and statements of operations, comprehensive income, changes in stockholders’ equity, and cash flows include the accounts of the Company and its wholly-owned subsidiary, after elimination of all intercompany transactions and accounts.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all money market funds and other investments purchased with an original maturity of three months or less to be cash and cash equivalents.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days . Collateral or any other security to support payment of these receivables generally is not required. The Company maintains an allowance for doubtful accounts, which is an estimate regularly evaluated by the Company for adequacy by taking into consideration factors such as past experience, credit quality of the customer base, age of the receivable balances, both individually and in the aggregate, and current economic conditions that may affect a customer’s ability to pay. Provisions for the allowance for doubtful accounts attributed to bad debt are recorded in general and administrative expenses. The following table shows the allowance for doubtful accounts activity: Amount Balance at June 30, 2016 $ 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 800 Provision for doubtful accounts 125 Write-offs (312 ) Balance at June 30, 2019 $ 613
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out method of valuation. The establishment of inventory allowances for excess and obsolete inventories is based on estimated exposure on specific inventory items. The Company writes down its inventories as it becomes aware of any situation where the carrying amount exceeds the estimated realizable value based on assumptions about future demands and market conditions.
Property and Equipment	Property and Equipment Property and equipment is carried at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over estimated useful lives of 40 years for the building; five years to seven years for production equipment and furniture and fixtures; three years for computer equipment and software; and the shorter of their estimated useful lives or the lease term for leasehold improvements. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. All other expenditures for renewals and betterments are capitalized. The assets and related depreciation accounts are adjusted for property retirements and disposals with the resulting gains or losses included in the consolidated statement of operations.
Patents	Patents The capitalized costs incurred to obtain patents are amortized using the straight-line method over their remaining estimated lives. Patent amortization begins at the time of patent application approval, and does not exceed 20 years . The recoverability of capitalized patent costs is dependent upon the Company’s ability to derive revenue-producing products from such patents or the ultimate sale or licensing of such patent rights. Patent recoverability is regularly reviewed and any patents that are abandoned are written off at the time of abandonment.
Long-Lived Assets	Long-Lived Assets The Company regularly evaluates the carrying value of long-lived assets for events or changes in circumstances that indicate that the carrying amount may not be recoverable or that the remaining estimated useful life should be changed. An impairment loss is recognized when the carrying amount of an asset exceeds the anticipated future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. The amount of the impairment loss to be recorded, if any, is calculated by the excess of the asset’s carrying value over its fair value.
Operating Leases	Operating Leases The Company leases its Texas manufacturing facilities under an operating lease agreement. The lease contains rent escalation clauses for which the lease expense is recognized on a straight-line basis over the lease term. Rent expense that is recognized but not yet paid is included in other liabilities on the consolidated balance sheets.
Financing Obligation	Financing Obligation In March 2017, the Company entered into an agreement to lease its Minnesota facility. The lease agreement has an initial term of fifteen years , with four consecutive renewal options of five years each at the Company's option. As the lease terms resulted in a capital lease classification, the Company accounted for the sale and leaseback of its Minnesota facility as a financing transaction where the assets remain on the Company's balance sheet and a financing obligation was recorded for $20,944 . As lease payments are made, they will be allocated between interest expense and a reduction of the financing obligation, resulting in a value of the financing obligation that is equivalent to the net book value of the assets at the end of the lease term. At the end of the lease (including any renewal option terms), the Company will remove the assets and financing obligation from its balance sheet.
Warranty Costs	Warranty Costs The Company provides its customers with the right to receive a replacement if a product is determined to be defective at the time of shipment. Warranty reserve provisions are estimated based on Company experience, volume, and expected warranty claims. Warranty reserve, provisions and claims were as follows: Amount Balance at June 30, 2016 $ 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 132 Provision 502 Claims (501 ) Balance at June 30, 2019 $ 133
Litigation and Contingent Liabilities	Litigation and Contingent Liabilities The Company and its operations from time to time are, and in the future may be, parties to or targets of lawsuits, claims, investigations, and proceedings, which are handled and defended in the ordinary course of business. The Company accrues a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When a single amount cannot be reasonably estimated but the cost can be estimated within a range, the Company accrues an amount based on management’s best estimate considering all facts and circumstances. The Company expenses legal costs, including those expected to be incurred in connection with a loss contingency, as incurred.
Medical Device Excise Tax	Medical Device Excise Tax The Patient Protection and Affordable Care Act of 2010 imposed a medical device excise tax on medical device manufacturers on their sales in the United States of certain devices, which was effective January 1, 2013. The excise tax is 2.3% of the taxable base and applied to a substantial majority of the Company’s sales. Effective January 1, 2016, the excise tax was suspended until the end of 2017, and in January 2018, another temporary two year suspension of the tax was passed, extending the suspension to December 31, 2019.
Income Taxes	Income Taxes Deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts based on enacted tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Developing a provision for income taxes, including the effective tax rate and the analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred tax assets. The Company’s judgment and tax strategies are subject to audit by various taxing authorities. Accounting guidance requires that accounting for uncertainty in income taxes is recognized in the financial statements. The guidance provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Income tax positions must meet a more-likely-than-not recognition threshold to be recognized. The guidance also provides rules on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.
Research and Development Expenses	Research and Development Expenses Research and development expenses include costs associated with the design, development, testing, enhancement and regulatory approval of the Company’s products. Research and development expenses include employee compensation (including stock-based compensation), supplies and materials, consulting expenses, patent amortization and fees, travel and facilities overhead. The Company also incurs significant expenses to operate clinical trials, including trial design, third-party fees, clinical site reimbursement, data management and travel expenses. Research and development expenses are expensed as incurred.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains its cash balances primarily with one financial institution. These balances exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base.
Marketable Securities	Marketable Securities The Company’s marketable securities consist predominately of available-for-sale debt securities and were valued in accordance with the fair value measurement guidance. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ equity as accumulated other comprehensive income, net of tax. Realized gains and losses, if any, are calculated on the specific identification method and are included in interest and other, net in the consolidated statements of operations. Available-for-sale equity securities are carried at fair value with any unrealized gains or losses reported in earnings. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported in equity as accumulated other comprehensive income.
Fair Value Measurements	Fair Value Measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of June 30, 2019 , the Company believes that the carrying amounts of its other financial instruments, including accounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4 for additional information.
Use of Estimates	Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and these differences could be material.
Stock-Based Compensation	Stock-Based Compensation The Company has stock-based compensation plans, which include stock options, nonvested share awards, and an employee stock purchase plan. Fair value of option awards is determined using option-pricing models, fair value of nonvested share awards with market conditions is determined using the Monte Carlo simulation, and fair value of nonvested share awards that vest based upon performance or service conditions is determined by the closing market price of the Company’s stock on the date of grant. Stock-based compensation expense is recognized ratably over the requisite service period for the awards expected to vest.
Subsequent Events, Policy [Policy Text Block]	Subsequent Event On August 5, 2019, the Company acquired the WIRION Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd. Upon closing, the Company made an initial $5,600 cash outlay and issued Gardia 31,493 shares of Common Stock of the Company valued at $1,400 . Following the successful completion of the manufacturing transfer of the WIRION system to the Company, the Company has agreed to pay Gardia an additional $10,000 , half of which may be paid by the Company through an additional issuance of shares of Common Stock. In addition, the Company has agreed to make a performance milestone payment to Gardia equal to $3,000 for each $10,000 in net revenues recognized by the Company from sales of the WIRION system for applications above-the-knee in excess of $30,000 during the 36 month period beginning on the earlier of the first commercial sale of the system by the Company or six months following successful manufacturing transfer. The initial accounting for this acquisition will be completed in the first quarter of fiscal 2020.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, “Leases.” The guidance requires lessees to recognize the assets and liabilities that arise from leases on the balance sheet. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, and should be applied using a modified retrospective approach. The guidance is effective for the Company on July 1, 2019. The Company will elect the prospective transition method with the effects of adoption recognized as a cumulative effect adjustment to the opening balance of retained earnings in the Company's fiscal 2020 financial statements, with no restatement of comparative periods. The Company will also elect the package of three practical expedients permitted under the transition guidance within the new standard, which, among other things, allows the Company to carry forward the historical lease classification. The Company has assessed the impact of adopting this guidance on its consolidated financial statements and related disclosures and does not expect a material impact to its results of operations and cash flows. The Company will record its operating leases on its consolidated balance sheet as right of use assets and lease liabilities, but due to the makeup of its current operating lease portfolio, does not expect a material amount to be recognized on the consolidated balance sheet. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments,” which revises guidance for the accounting for credit losses on financial instruments within its scope. The new standard introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases and off-balance-sheet credit exposures. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted and should be applied as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. The guidance is effective for the Company on July 1, 2020. The Company does not anticipate a material impact on its financial statements upon adoption.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Allowance for doubtful accounts	Amount Balance at June 30, 2016 $ 712 Provision for doubtful accounts 465 Write-offs (313 ) Balance at June 30, 2017 864 Provision for doubtful accounts 125 Write-offs (189 ) Balance at June 30, 2018 800 Provision for doubtful accounts 125 Write-offs (312 ) Balance at June 30, 2019 $ 613
Warranty reserve, provisions and claims	Amount Balance at June 30, 2016 $ 145 Provision 1,733 Claims (1,361 ) Balance at June 30, 2017 517 Provision 328 Claims (713 ) Balance at June 30, 2018 132 Provision 502 Claims (501 ) Balance at June 30, 2019 $ 133

Selected Consolidated Financi_2

Selected Consolidated Financial Statement Information (Tables)	12 Months Ended
	Jun. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	June 30, 2019 2018 Accounts receivable $ 36,628 $ 32,025 Less: Allowance for doubtful accounts (613 ) (800 ) Accounts receivable, net $ 36,015 $ 31,225
Inventories	June 30, 2019 2018 Raw materials $ 5,547 $ 6,820 Work in process 1,415 1,315 Finished goods 11,096 8,470 Inventories $ 18,058 $ 16,605
Property and equipment	June 30, 2019 2018 Land $ 572 $ 500 Building 22,420 22,420 Equipment 17,517 16,510 Furniture 2,975 2,709 Leasehold improvements 540 438 Construction in progress 1,328 1,110 45,352 43,687 Less: Accumulated depreciation (18,028 ) (15,943 ) Total Property and equipment, net $ 27,324 $ 27,744
Patents, net	June 30, 2019 2018 Patents $ 6,093 $ 6,435 Less: Accumulated amortization (988 ) (1,204 ) Total Patents, net $ 5,105 $ 5,231
Patent amortization schedule	As of June 30, 2019, future estimated amortization of patents is as follows: 2020 $ 209 2021 209 2022 207 2023 201 2024 197 Thereafter 4,082 $ 5,105
Accrued expenses	June 30, 2019 2018 Salaries and bonus $ 11,105 $ 6,624 Commissions 6,829 7,234 Accrued vacation 4,230 3,557 Accrued excise, sales and other taxes 3,349 3,522 Clinical studies 2,092 1,422 Legal settlement 467 1,847 Other accrued expenses 1,315 1,570 Total Accrued expenses $ 29,387 $ 25,776

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Year Ended June 30, Product Category 2019 2018 2017 Peripheral $ 178,896 $ 161,405 $ 153,716 Coronary 69,121 55,638 51,190 Total net revenues $ 248,017 $ 217,043 $ 204,906 Geography United States $ 240,114 $ 215,233 $ 204,906 International 7,903 1,810 — Total net revenues $ 248,017 $ 217,043 $ 204,906

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of future minimum lease payments	2020 $ 1,750 2021 1,803 2022 1,857 2023 1,913 2024 1,970 Thereafter 17,405 $ 26,698

Marketable Securities & Fair _2

Marketable Securities & Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2019
Compensation Related Costs [Abstract]
Marketable Securities [Table Text Block]	June 30, 2019 2018 Short-term available-for-sale debt securities $ 38,193 $ — Long-term available-for-sale debt securities 9,832 — Available-for-sale debt securities 48,025 — Mutual funds 410 544 Total marketable securities $ 48,435 $ 544
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	As of June 30, 2019 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 14,277 $ — $ — $ 14,277 Corporate debt 26,466 64 — 26,530 Asset backed securities 7,204 14 — 7,218 Total available-for-sale debt securities $ 47,947 $ 78 $ — $ 48,025
Available-for-sale marketable securities at fair value on recurring basis	Fair Value Measurements as of June 30, 2019 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Commercial paper $ 14,277 — 14,277 $ — Corporate debt $ 26,530 — 26,530 $ — Asset backed securities $ 7,218 — 7,218 $ — Mutual funds $ 410 121 289 $ — Total marketable securities $ 48,435 121 48,314 $ — Fair Value Measurements as of June 30, 2018 Using Inputs Considered as Fair Value Level 1 Level 2 Level 3 Mutual funds $ 544 199 345 $ — Total marketable securities $ 544 199 345 $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock option activity	Number of Options Weighted Average Exercise Price Options outstanding at June 30, 2016 606,879 $ 10.14 Exercised (519,297 ) $ 10.33 Forfeited or expired (9,381 ) $ 8.83 Options outstanding at June 30, 2017 78,201 $ 9.07 Exercised (55,880 ) $ 9.20 Options outstanding at June 30, 2018 22,321 $ 8.75 Exercised (22,321 ) $ 8.75 Options outstanding at June 30, 2019 — $ —
Restricted stock award activity	Number of Shares Weighted Average Grant Date Fair Value Outstanding at June 30, 2016 647,573 $ 23.24 Granted 258,346 $ 21.80 Forfeited (103,140 ) $ 22.11 Vested (316,195 ) $ 24.21 Outstanding at June 30, 2017 486,584 $ 21.26 Granted 290,856 $ 27.93 Forfeited (68,499 ) $ 22.76 Vested (253,725 ) $ 22.87 Outstanding at June 30, 2018 455,216 $ 24.77 Granted 262,727 $ 35.53 Forfeited (27,143 ) $ 29.05 Vested (215,855 ) $ 23.23 Outstanding at June 30, 2019 474,945 $ 31.36
Aggregate maximum performance-based restricted stock awards granted	Performance Measurement 2019 2018 2017 Total shareholder return 225,325 278,889 336,826
Performance-based restricted stock award activity	Number of Weighted Average Outstanding at June 30, 2016 310,111 $ 16.67 Granted 336,826 $ 11.97 Forfeited (328,353 ) $ 16.41 Outstanding at June 30, 2017 318,584 $ 11.97 Granted 278,889 $ 13.63 Forfeited (66,295 ) $ 13.17 Outstanding at June 30, 2018 531,178 $ 12.69 Granted 225,325 $ 22.33 Forfeited (2,631 ) $ 18.64 Outstanding at June 30, 2019 753,872 $ 15.20
Restricted stock unit activity	Number of Shares Weighted Average Grant Date Fair Value Restricted stock units outstanding at June 30, 2016 304,816 $ 13.95 Granted 54,064 $ 21.21 Converted to common stock (6,476 ) $ 29.34 Forfeited (2,974 ) $ 21.01 Restricted stock units outstanding at June 30, 2017 349,430 $ 14.73 Granted 28,364 $ 31.02 Converted to common stock (41,925 ) $ 16.07 Restricted stock units outstanding at June 30, 2018 335,869 $ 15.94 Granted 21,162 $ 38.28 Converted to common stock (2,855 ) $ 21.01 Restricted stock units outstanding at June 30, 2019 354,176 $ 17.23
Stock-based compensation expense	Year Ended June 30, 2019 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 281 $ — $ 65 $ 346 Selling, general and administrative 7,899 810 905 9,614 Research and development 1,136 — 170 1,306 Total stock-based compensation expense $ 9,316 $ 810 $ 1,140 $ 11,266 Year Ended June 30, 2018 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 207 $ — $ 68 $ 275 Selling, general and administrative 7,462 750 848 9,060 Research and development 817 — 150 967 Total stock-based compensation expense $ 8,486 $ 750 $ 1,066 $ 10,302 Year Ended June 30, 2017 Restricted Stock Awards Restricted Stock Units Employee Stock Purchase Plan Total Cost of goods sold $ 588 $ — $ 101 $ 689 Selling, general and administrative 6,568 1,024 1,065 8,657 Research and development 879 — 129 1,008 Total stock-based compensation expense $ 8,035 $ 1,024 $ 1,295 $ 10,354

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Deferred tax assets and liabilities	June 30, 2019 2018 Deferred tax assets Stock-based compensation $ 3,803 $ 2,505 Deferred revenue 2,032 2,351 Accrued expenses and compensation 1,058 1,103 Other 1,062 1,022 Research and development credit carryforwards 5,161 5,048 Net operating loss carryforwards 65,628 64,101 Total deferred tax assets 78,744 76,130 Valuation allowance (78,744 ) (76,130 ) Net deferred tax assets $ — $ —
Summary of valuation allowances	Balances at June 30, 2016 $ 101,217 Reductions (186 ) Balance at June 30, 2017 101,031 Reductions (24,901 ) Balance at June 30, 2018 76,130 Additions 2,614 Balance at June 30, 2019 $ 78,744
Reconciliation of beginning and ending amount of unrecognized tax benefits	Balances at June 30, 2016 $ 545 Decreases related to prior year tax positions (8 ) Increases related to current year tax positions 33 Balances at June 30, 2017 570 Decreases related to prior year tax positions (3 ) Increases related to current year tax positions 30 Balance at June 30, 2018 597 Decreases related to prior year tax positions (11 ) Increases related to current year tax positions 25 Balance at June 30, 2019 $ 611

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments	2020 $ 392 2021 36 2022 8 2023 3 2024 2 Thereafter — $ 441

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators used in the basic and diluted earnings per common share computations	Year Ended June 30, 2019 2018 2017 Numerator Net income (loss) $ (255 ) $ 1,712 $ (1,792 ) Income allocated to participating securities — (19 ) — Net income (loss) available to common stockholders $ (255 ) $ 1,693 $ (1,792 ) Denominator Weighted average common shares outstanding — basic 33,535,759 33,145,140 32,373,709 Effect of dilutive stock options (1) — 15,039 — Effect of dilutive restricted stock units (2) — 335,869 — Effect of performance-based restricted stock awards (3) — 118,212 — Weighted average common shares outstanding — diluted 33,535,759 33,614,260 32,373,709 Earnings per common share — basic $ (0.01 ) $ 0.05 $ (0.06 ) Earnings per common share — diluted $ (0.01 ) $ 0.05 $ (0.06 ) (1) At June 30, 2018 , and 2017 ; 22,321 , and 78,201 stock options, respectively, were outstanding. The effect of the shares that would be issued upon exercise of these options has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive. No stock options were outstanding at June 30, 2019. (2) At June 30, 2019 , 2018 , and 2017 ; 354,176 , 335,869 and 349,430 additional shares of common stock, respectively, were issuable upon the settlement of outstanding restricted stock units. The effect of the shares that would be issued upon settlement of these restricted stock units has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive. (3) At June 30, 2019 , 2018 , and 2017 ; 753,872 , 531,178 , and 318,584 respectively, of performance-based restricted stock awards were outstanding. The effect of the shares that would be issued upon vesting of these awards has been excluded from the calculation of diluted loss per share as of June 30, 2019, and 2017, because those shares are anti-dilutive.

Quarterly Data (Unaudited) (Tab

Quarterly Data (Unaudited) (Tables)	12 Months Ended
	Jun. 30, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of quarterly financial information	2019 Q1 Q2 Q3 Q4 Year Total Net revenue $ 56,266 $ 60,206 $ 63,311 $ 68,234 $ 248,017 Gross profit $ 45,691 $ 48,729 $ 51,145 $ 54,772 $ 200,337 Net income (loss) $ (2,888 ) $ 492 $ 672 $ 1,469 $ (255 ) Earnings per common share - basic (1) $ (0.09 ) $ 0.01 $ 0.02 $ 0.04 $ (0.01 ) Earnings per common share - diluted (1) $ (0.09 ) $ 0.01 $ 0.02 $ 0.04 $ (0.01 ) 2018 Q1 Q2 Q3 Q4 Year Total Net revenue $ 49,676 $ 52,628 $ 55,587 $ 59,152 $ 217,043 Gross profit $ 40,474 $ 43,129 $ 45,618 $ 48,338 $ 177,559 Net income (loss) $ (1,977 ) $ (413 ) $ 365 $ 3,737 $ 1,712 Earnings per common share - basic (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 Earnings per common share - diluted (1) $ (0.06 ) $ (0.01 ) $ 0.01 $ 0.11 $ 0.05 (1) The summation of quarterly per share data may not equate to the calculation for the full fiscal year as quarterly calculations are performed on a discrete basis.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2019USD ($)renewal_termfinancial_institution
Accounting Policies [Abstract]
Accounts receivable credit period	30 days
Property and Equipment and Patents [Line Items]
Finance lease, term of contract	15 years
Finance lease, renewal options | renewal_term	4
Finance lease, renewal term	5 years
Medical device excise tax, percentage	2.30%
Contract with customer, liability | $	$ 10,000
Number of financial institutions the company maintains its cash balances | financial_institution	1
Building
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	40 years
Computer Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	3 years
Minimum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	5 years
Maximum
Property and Equipment and Patents [Line Items]
Patent amortization tenure	20 years
Maximum | Equipment
Property and Equipment and Patents [Line Items]
Property and equipment, estimated useful life	7 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Allowance for Doubtful Accounts Activity) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Accounting Policies [Abstract]
Accounts Receivable Credit Period	30 days
Allowance for doubtful accounts activity
Beginning balance	$ 800	$ 864	$ 712
Provision for doubtful accounts	125	125	465
Write-offs	(312)	(189)	(313)
Ending balance	$ 613	$ 800	$ 864

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Warranty Reserve) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Warranty reserve, provisions and claims
Beginning balance	$ 132	$ 517	$ 145
Provision	502	328	1,733
Claims	(501)	(713)	(1,361)
Ending balance	$ 133	$ 132	$ 517

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Subsequent Events) (Details) - USD ($) $ in Thousands	Aug. 05, 2019	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Subsequent Event [Line Items]
Cash payment to acquire intangible assets		$ 890	$ 1,113	$ 844
WIRION Embolic Protection System | Subsequent Event
Subsequent Event [Line Items]
Cash payment to acquire intangible assets	$ 5,600
Shares issued (in shares)	31,493
Value of shares issued for acquisition	$ 1,400
Additional consideration, pending disbursement	10,000
Potential milestone payment	3,000
Milestone payment target, increment in net revenues	10,000
Milestone payment target, excess threshold	$ 30,000
Period for milestone payments, successful manufacture transfer	36 months

Selected Consolidated Financi_3

Selected Consolidated Financial Statement Information (Accounts Receivable, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Accounts receivable	$ 36,628	$ 32,025
Less: Allowance for doubtful accounts	(613)	(800)
Accounts receivable, net	$ 36,015	$ 31,225

Selected Consolidated Financi_4

Selected Consolidated Financial Statement Information (Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Raw materials	$ 5,547	$ 6,820
Work in process	1,415	1,315
Finished goods	11,096	8,470
Inventories	$ 18,058	$ 16,605

Selected Consolidated Financi_5

Selected Consolidated Financial Statement Information (Property and Equipment) (Details) - USD ($)	Mar. 30, 2017	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 45,352,000	$ 43,687,000
Less: Accumulated depreciation		(18,028,000)	(15,943,000)
Total Property and equipment, net		27,324,000	27,744,000
Sale Agreement
Facility Purchase Price	$ 21,500,000
Net Proceeds on Sale of the Facility	20,944,000
Transaction Costs, Sale Leaseback	556,000
Gain (Loss) on Sale of Assets and Asset Impairment Charges	$ 158,000
Land
Property, Plant and Equipment [Line Items]
Total Property and equipment		572,000	500,000
Building
Property, Plant and Equipment [Line Items]
Total Property and equipment		22,420,000	22,420,000
Equipment
Property, Plant and Equipment [Line Items]
Total Property and equipment		17,517,000	16,510,000
Furniture
Property, Plant and Equipment [Line Items]
Total Property and equipment		2,975,000	2,709,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total Property and equipment		540,000	438,000
Construction in progress
Property, Plant and Equipment [Line Items]
Total Property and equipment		$ 1,328,000	$ 1,110,000

Selected Consolidated Financi_6

Selected Consolidated Financial Statement Information (Patents, Net) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Patents	$ 6,093	$ 6,435
Less: Accumulated amortization	(988)	(1,204)
Total Patents	$ 5,105	$ 5,231

Selected Consolidated Financi_7

Selected Consolidated Financial Statement Information (Estimated Amortization of Patents) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018
Estimated amortization of patents and patent licenses
2019	$ 209
2020	209
2021	207
2022	201
2023	197
Thereafter	4,082
Total Patents	$ 5,105	$ 5,231

Selected Consolidated Financi_8

Selected Consolidated Financial Statement Information (Accrued Expenses) (Details) $ in Thousands	Jun. 28, 2016USD ($)installment_paymentRate	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
Accrued expenses
Salaries and bonus		$ 11,105	$ 6,624
Commissions		6,829	7,234
Accrued vacation		4,230	3,557
Accrued excise, sales and other taxes		3,349	3,522
Clinical studies		2,092	1,422
Legal settlement		467	1,847
Other accrued expenses		1,315	1,570
Total Accrued expenses		$ 29,387	$ 25,776
Legal settlement
Litigation Settlement, Amount Awarded to Other Party	$ 8,000
Payments for Legal Settlements	3,000
Settlement Payable in Installments	$ 5,000
Litigation Settlement Interest, Percentage | Rate	1.80%
Litigation Settlement, Number of Quarterly Installment Payment | installment_payment	11
Single payment threshold amount	$ 2,000

Revenue - Dissagregate (Details

Revenue - Dissagregate (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Net revenues	$ 68,234	$ 63,311	$ 60,206	$ 56,266	$ 59,152	$ 55,587	$ 52,628	$ 49,676	$ 248,017	$ 217,043	$ 204,906
United States
Disaggregation of Revenue [Line Items]
Net revenues									240,114	215,233	204,906
International
Disaggregation of Revenue [Line Items]
Net revenues									7,903	1,810	0
Peripheral
Disaggregation of Revenue [Line Items]
Net revenues									178,896	161,405	153,716
Coronary
Disaggregation of Revenue [Line Items]
Net revenues									$ 69,121	$ 55,638	$ 51,190

Revenue - Narratives (Details)

Revenue - Narratives (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
Revenue recognized previously deferred	$ 1,312
Volume-based rebates, discounts and incentives, current	$ 1,958	$ 1,398

Debt (Revolving Credit Facility

Debt (Revolving Credit Facility) (Details) - USD ($)	Mar. 31, 2017	Jun. 30, 2019	Mar. 31, 2018
Debt Instrument [Line Items]
Document Period End Date		Jun. 30, 2019
Revolving Credit Facility [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Percentage of Eligible Accounts Receivable			85.00%
Revolving Credit Facility [Member] | Silicon Valley Bank [Member] | Maximum [Member]
Debt Instrument [Line Items]
Borrowings Available On A Formula Basis			$ 10,000,000
Revolving Credit Facility [Member] | Silicon Valley Bank [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 40,000,000
Line of Credit Facility, Expiration Date	Mar. 31, 2020
Percent Reduction to Prime Interest Rate	0.25%
Percent of Eligible Inventory	50.00%
Maximum Eligible Inventory Value	$ 5,000,000
Early Termination Fee			1.00%
Covenant, Minimum Unused Availability	10,000,000
Covenant, Adjusted EBITDA	$ 1,000,000
Interest Rate Increase For Noncompliance	5.00%
Line of Credit Facility, Commitment Fee Amount	$ 80,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.35%
Number of Days for Collateral Examination	90 days
Line of Credit Facility, Fair Value of Amount Outstanding		$ 0

Debt (Financing Obligation) (De

Debt (Financing Obligation) (Details) - Financing Obligation [Member] $ in Thousands	3 Months Ended
	Jun. 30, 2019USD ($)optionsRate
Capital Lease Obligations
Capital lease term of contract (in years)	15 years
Capital lease number of renewal options | options	4
Capital lease term of renewal (in years)	5 years
Annual base rent	$ 1,638
Annual interest rate escalations (as a percent) | Rate	3.00%
Effective interest rate (as a percent) | Rate	7.89%
Capital Leases, Future Payments
Capital Leases, Future Minimum Payments Due, Next Twelve Months	$ 1,750
Capital Leases, Future Minimum Payments Due in Two Years	1,803
Capital Leases, Future Minimum Payments Due in Three Years	1,857
Capital Leases, Future Minimum Payments Due in Four Years	1,913
Capital Leases, Future Minimum Payments Due in Five Years	1,970
Capital Leases, Future Minimum Payments Due Thereafter	17,405
Capital Leases, Future Minimum Payments Due	$ 26,698

Marketable Securities & Fair _3

Marketable Securities & Fair Value Measurements (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Other-than-temporary impairments	$ 0	$ 0
Interest and Other, Net
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Realized gain		$ 34,000
Accrued Expenses
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	82,000
Other Liabilities
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Deferred compensation payable, current	$ 328,000

Marketable Securities & Fair _4

Marketable Securities & Fair Value Measurements (Investments) (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Investment [Line Items]
Equity Securities without Readily Determinable Fair Value, Amount	$ 5,593
Cumulative Effect of New Accounting Principle in Period of Adoption		$ 101,000
Fair Value	$ 48,025,000	0
Cost Method Investments		$ 2,538

Marketable Securities & Fair _5

Marketable Securities & Fair Value Measurements (Available-for-sale Securities on Recurring Basis) (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Current	$ 38,193,000	$ 0
Available-for-sale Securities, Noncurrent	9,832,000	0
Amortized Cost	47,947,000
Unrealized Gains	78,000
Unrealized Losses	0
Available-for-sale debt securities	48,025,000	0
Total marketable securities	48,435,000	544,000
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount	0
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount	0
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	14,277,000
Unrealized Gains	0
Unrealized Losses	0
Available-for-sale debt securities	14,277,000
Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	26,466,000
Unrealized Gains	64,000
Unrealized Losses	0
Available-for-sale debt securities	26,530,000
Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	7,204,000
Unrealized Gains	14,000
Unrealized Losses	0
Available-for-sale debt securities	7,218,000
Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total marketable securities	410,000	544,000
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	48,435,000	544,000
Recurring | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	14,277,000
Recurring | Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	26,530,000
Recurring | Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	7,218,000
Recurring | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	410,000	544,000
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	121,000	199,000
Recurring | Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 1 | Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 1 | Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 1 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	121,000	199,000
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	48,314,000	345,000
Recurring | Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	14,277,000
Recurring | Level 2 | Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	26,530,000
Recurring | Level 2 | Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	7,218,000
Recurring | Level 2 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	289,000	345,000
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0	0
Recurring | Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 3 | Corporate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 3 | Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0
Recurring | Level 3 | Mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities	0	$ 0
Other Liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation payable, current	$ 328,000

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	0	22,321	78,201	606,879
Options granted	0	0	0
Aggregate intrinsic value for vested and outstanding options	$ 0	$ 527,000	$ 1,811,000
Total aggregate intrinsic value of options exercised	$ 553,000	$ 1,095,000	$ 7,955,000
Forfeiture rate	18.00%	15.20%	17.10%
Total compensation cost for non-vested awards not yet recognized	$ 11,016,000
Share-based Payment Arrangement, Expense	$ 11,266,000	$ 10,302,000	$ 10,354,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period expected to recognize nonvested awards	1 year 7 months 6 days
Share-based Payment Arrangement, Expense	$ 9,316,000	8,486,000	8,035,000
Restricted Stock Awards | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Awards | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost for non-vested awards not yet recognized	$ 4,078
Weighted-average period expected to recognize nonvested awards	1 year 9 months 18 days
Share-based Payment Arrangement, Expense	$ 3,497,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 1,140,000	$ 1,066,000	$ 1,295,000
Maximum period for payment on restricted stock unit following the six month anniversary date	30 days
Minimum period after grant date	2 years
2017 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock approved	3,607,523
Shares available for grant	2,085,025

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Option Activity) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of Options
Beginning balance (in shares)	22,321	78,201	606,879
Exercised (in shares)	(22,321)	(55,880)	(519,297)
Forfeited or expired			$ (9,381)
Ending balance (in shares)	0	22,321	78,201
Weighted Average Exercise Price
Beginning balance (in usd per share)	$ 8.75	$ 9.07	$ 10.14
Exercised (in usd per share)	8.75	9.20	10.33
Forfeited or expired (in usd per share)			8.83
Ending balance (in usd per share)	$ 0	$ 8.75	$ 9.07

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock) (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of Shares
Outstanding at beginning of period (in shares)	455,216	486,584	647,573
Granted (in shares)	262,727	290,856	258,346
Forfeited (in shares)	(27,143)	(68,499)	(103,140)
Vested (in shares)	(215,855)	(253,725)	(316,195)
Outstanding at end of period (in shares)	474,945	455,216	486,584
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 24.77	$ 21.26	$ 23.24
Forfeited (in usd per share)	29.05	22.76	22.11
Granted (in usd per share)	35.53	27.93	21.80
Vested (in usd per share)	23.23	22.87	24.21
Outstanding at end of period (in usd per share)	$ 31.36	$ 24.77	$ 21.26

Stock-Based Compensation (Maxim

Stock-Based Compensation (Maximum Performance Shares Granted) (Details) - Performance Shares - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	225,325	278,889	336,826
Total Shareholder Return
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance Measurement (in shares)	225,325	278,889	336,826

Stock-Based Compensation (Perfo

Stock-Based Compensation (Performance Based Restricted Stock Awards) (Details) - shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	(2,631)	(66,295)	(328,353)

Stock-Based Compensation (Per_2

Stock-Based Compensation (Performace-based Restricted Stock Award Activity) (Details) - Performance Shares - $ / shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of Shares
Outstanding at beginning of period (in shares)	531,178	318,584	310,111
Granted (in shares)	225,325	278,889	336,826
Forfeited (in shares)	(2,631)	(66,295)	(328,353)
Outstanding at end of period (in shares)	753,872	531,178	318,584
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 12.69	$ 11.97	$ 16.67
Granted (in usd per share)	22.33	13.63	11.97
Forfeited (in usd per share)	18.64	13.17	16.41
Outstanding at end of period (in usd per share)	$ 15.20	$ 12.69	$ 11.97

Stock-Based Compensation (Res_2

Stock-Based Compensation (Restricted Stock Unit Activity) (Details) - Employee Stock Purchase Plan - $ / shares	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Number of Shares
Outstanding at beginning of period (in shares)	335,869	349,430	304,816
Granted (in shares)	21,162	28,364	54,064
Forfeited (in shares)		(41,925)	(2,974)
Converted to common stock (in shares)	(2,855)		(6,476)
Outstanding at end of period (in shares)	354,176	335,869	349,430
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 15.94	$ 14.73	$ 13.95
Granted (in usd per share)	38.28	31.02	21.21
Forfeited (in usd per share)		16.07	21.01
Converted to common stock	21.01		29.34
Outstanding at end of period (in usd per share)	$ 17.23	$ 15.94	$ 14.73

Stock-Based Compensation (Sto_2

Stock-Based Compensation (Stock-based Compensation Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 11,266	$ 10,302	$ 10,354
Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	9,316	8,486	8,035
Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	810	750	1,024
Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,140	1,066	1,295
Cost of goods sold
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	346	275	689
Cost of goods sold | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	281	207	588
Cost of goods sold | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	0	0
Cost of goods sold | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	65	68	101
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	9,614	9,060	8,657
Selling, general and administrative | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	7,899	7,462	6,568
Selling, general and administrative | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	810	750	1,024
Selling, general and administrative | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	905	848	1,065
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,306	967	1,008
Research and development | Restricted Stock Awards
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,136	817	879
Research and development | Restricted Stock Units
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	0	0	0
Research and development | Employee Stock Purchase Plan
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 170	$ 150	$ 129

Stock-Based Compensation (Emplo

Stock-Based Compensation (Employee Stock Purchase Plan) (Details) - Employee Stock Purchase Plan [Member]	12 Months Ended
	Jun. 30, 2019$ / sharesRateshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Purchase Period	6 months
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | Rate	85.00%
Stock Issued During Period, Shares, Employee Stock Ownership Plan	155,394
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased | $ / shares	$ 24.14
Employee Stock Ownership Plan (ESOP), Number of Allocated Shares	1,530,037

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Deferred tax assets
Stock-based compensation	$ 3,803	$ 2,505
Deferred revenue	2,032	2,351
Accrued expenses and compensation	1,058	1,103
Other	1,062	1,022
Research and development credit carryforwards	5,161	5,048
Net operating loss carryforwards	65,628	64,101
Total deferred tax assets	78,744	76,130
Valuation allowance	(78,744)	(76,130)	$ (101,031)	$ (101,217)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Valuation Allowan

Income Taxes (Valuation Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Summary of valuation allowances
Beginning balance	$ 76,130	$ 101,031	$ 101,217
Reductions	2,614	(24,901)	(186)
Ending balance	$ 78,744	$ 76,130	$ 101,031

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Operating Loss Carryforwards [Line Items]
Liability relating to unrecognized tax benefits	$ 611	$ 597	$ 570	$ 545
Federal
Operating Loss Carryforwards [Line Items]
Tax NOL carryforwards	269,433	275,030
Research and development credit carryforwards	4,314	4,244
State
Operating Loss Carryforwards [Line Items]
Research and development credit carryforwards	$ 1,798	$ 1,560

Income Taxes (Unrecognized Tax

Income Taxes (Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Reconciliation of beginning and ending amount of unrecognized tax benefits
Beginning balance	$ 597	$ 570	$ 545
Decreases related to prior year tax positions	(11)	(3)	(8)
Increases related to current year tax positions	(25)	(30)	(33)
Ending balance	$ 611	$ 597	$ 570

Commitments and Contingencies_2

Commitments and Contingencies (Operating Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Rental expenses	$ 540	$ 652	$ 656
Operating Leases, Future Minimum Payments Receivable [Abstract]
2019	392
2020	36
2021	8
2022	3
2023	2
Thereafter	0
Total	$ 441

Employee Benefits (Details)

Employee Benefits (Details) - USD ($)	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Defined Benefit Plan Disclosure [Line Items]
Contribution by employee in plan	$ 19,000
Age of eligible employees for contribute additional amount	50 years
Additional contribution by employee in plan	$ 6,000
Minimum age for qualifying in 401(a) plan	21 years
Document Period End Date	Jun. 30, 2019
Employer matching contributions	$ 0	$ 0	$ 0
Other Liabilities
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation payable, current	328,000
Accrued Expenses
Defined Benefit Plan Disclosure [Line Items]
Deferred compensation payable, current	$ 82,000

Earnings Per Share (Reconciliat

Earnings Per Share (Reconciliation of Numerators and Denominators) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	34,934,569				33,360,032				34,934,569	33,360,032
Numerator
Net (loss) income	$ 1,469	$ 672	$ 492	$ (2,888)	$ 3,737	$ 365	$ (413)	$ (1,977)	$ (255)	$ 1,712	$ (1,792)
Undistributed Earnings (Loss) Allocated to Participating Securities, Basic									0	(19)	0
Undistributed Earnings (Loss) Available to Common Shareholders, Basic									$ (255)	$ 1,693	$ (1,792)
Denominator
Weighted average common shares - basic (in shares)									33,535,759	33,145,140	32,373,709
Weighted average common shares outstanding - diluted (in shares)									33,535,759	33,614,260	32,373,709
Earnings per common share — basic	$ 0.04	$ 0.02	$ 0.01	$ (0.09)	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ (0.01)	$ 0.05	$ (0.06)
Earnings per common share — diluted	$ 0.04	$ 0.02	$ 0.01	$ (0.09)	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ (0.01)	$ 0.05	$ (0.06)
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding					22,321					22,321	78,201
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									0	15,039	0
Employee Stock Purchase Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	354,176				335,869				354,176	335,869	349,430
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									0	335,869	0
Performance Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding	753,872				531,178				753,872	531,178	318,584
Denominator
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements									0	118,212	0

Earnings Per Share (Details Tex

Earnings Per Share (Details Textual) - shares	3 Months Ended
	Sep. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding		34,934,569	33,360,032
Undistributed earnings allocation, number unvested time-based shares	382,476
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding			22,321	78,201
Employee Stock Purchase Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding		354,176	335,869	349,430
Performance Shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock, shares outstanding		753,872	531,178	318,584

Quarterly Data (Unaudited) (Det

Quarterly Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]
Net revenues	$ 68,234	$ 63,311	$ 60,206	$ 56,266	$ 59,152	$ 55,587	$ 52,628	$ 49,676	$ 248,017	$ 217,043	$ 204,906
Gross profit	54,772	51,145	48,729	45,691	48,338	45,618	43,129	40,474	200,337	177,559	165,465
Net (loss) income	$ 1,469	$ 672	$ 492	$ (2,888)	$ 3,737	$ 365	$ (413)	$ (1,977)	$ (255)	$ 1,712	$ (1,792)
Earnings per common share — basic	$ 0.04	$ 0.02	$ 0.01	$ (0.09)	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ (0.01)	$ 0.05	$ (0.06)
Earnings per common share — diluted	$ 0.04	$ 0.02	$ 0.01	$ (0.09)	$ 0.11	$ 0.01	$ (0.01)	$ (0.06)	$ (0.01)	$ 0.05	$ (0.06)